A Phase III trial showed equivalence but not superiority for the Neopharm CED toxin for glioma. See also….
This entry was posted on Tuesday, December 12th, 2006 at 11:36 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.